Revenue
13.4 million Unit_Standard_USD_tDKVxqiHJUuVh7TBH1scVA
2025 Q3 · Unit_Standard_USD_tDKVxqiHJUuVh7TBH1scVA
Exact inputs and evidence
- Revenue: 13360000 Unit_Standard_USD_tDKVxqiHJUuVh7TBH1scVA Source
132 filing records in this dataset, filed from 1999-07-30 to 2026-02-19. Reported financial figures are available; chart coverage varies by period.
13.4 million Unit_Standard_USD_tDKVxqiHJUuVh7TBH1scVA
2025 Q3 · Unit_Standard_USD_tDKVxqiHJUuVh7TBH1scVA
-329.06%
2025 Q3 · %
13300000 Unit_Standard_USD_tDKVxqiHJUuVh7TBH1scVA
3964000 Unit_Standard_USD_jTxptVfSSU-ujCxIdH7s_w
30336201 Unit_Standard_shares_aLLOWFPR-UWkFFpe8LkIIQ
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-02-19.
Financial data available through: 2024-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
No unambiguous prior-year comparison is available for the latest reporting period.
Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value | Source evidence |
|---|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|
Cash generated by the company’s normal business operations.
| Period | Series | Value | Source evidence |
|---|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value | Source evidence |
|---|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
No compatible annual cash generation figures are available for this company.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
132 filings · 6,878 latest values · 6,878 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000846475, 846475, ZYXI, ZYXIQ, edgar:846475
Also known as ARIZONA VENTURES INC, CHINA GLOBAL DEVELOPMENT INC, FOX RIVER HOLDINGS INC, IBONZAI COM INC, LIFE MEDICAL TECHNOLOGIES INC /UT/, ZYNEX INC, ZYNEX MEDICAL HOLDINGS INC, ZYNEX MEDICAL HOLDINGS INC, ZYNEX, INC., ZYNEX, INC., Zynex, Inc.